seladelpar
·Code: MBX-8025
seladelpar: developed by 1 company · 1 clinical trial tracked.
seladelpar evidence translation
What we can confirm
1 tracked trial
What it means
Source-backed records connect seladelpar to CBAY; that link alone does not prove the drug works.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
How could seladelpar → CBAY affect its developer, and what evidence supports the link?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 1 study sponsors
Related indications
Study sponsors
Development Pipeline (1)
| Company | Phase |
|---|---|
| CymaBay Therapeutics, Inc. (CBAY) | Phase 2 |
Clinical Trials (1)
AFFIRM: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
Primary endpoint: Event Free Survival (EFS)
InterventionalRandomizeddouble318 targetStarted 2023-09Completion 2030-0850 sites · United StatesGilead Sciences
Frequently asked questions
Who is developing seladelpar?
seladelpar is being developed by CymaBay Therapeutics, Inc..
How many clinical trials involve seladelpar?
BioSniper tracks 1 clinical trial involving seladelpar.